The stock climbed 4.81 per cent to settle at Rs 359.30 on BSE. During the day, it went up by 6.18 per cent to Rs 364.
On NSE, it soared 4.99 per cent to end at Rs 360.30.
Cadila Healthcare has received EIR from the US health regulator for its manufacturing facility in Moraiya, indicating "closure of the inspection points" of initial review in 2014.
This receipt of EIR only indicates closure of the inspection points (483s) raised based on the inspection carried out between August 28, 2014 and September 5, 2014, it added.
Also Read
"What is 'closed' is the initial review that resulted in the warning letter issuance," Cadila Healthcare said.
Though this is a positive step towards the resolution of the warning letter issued by the USFDA, it does not in itself indicate resolution of the warning letter, it added.